Monocarboxylate Transporter Inhibitor

H-HoArg-OH-d₄ (L-Homoarginine-d₄) is the d₄-labeled H-HoArg-OH (HY-W008385). H-HoArg-OH (L-Homoarginine) is an orally active endogenous non-protein amino acid. H-HoArg-OH acts as a weak alternative substrate for NOS and interferes with NO production, selectively inhibits tissue-nonspecific alkaline phosphatase (TNAP), and suppresses the uptake of arginine by y⁺-type transporters (system y⁺). H-HoArg-OH increases tissue hArg concentrations in vivo, regulates amino acid homeostasis, and improves renal function and pathological features of diabetic nephropathy. H-HoArg-OH can be used in studies related to diabetes and cardiomyopathy.

AR-C141990 hydrochloride is a potent lactate transporters (monocarboxylate transporters; MCTs) inhibitor with pK_i values of 7.6, 6.6 for MCT-1 and MCT-2, respectively. AR-C141990 hydrochloride has immunosuppressive properties and inhibits graft versus host response.

H-HoArg-OH-d₄ dihydrochloride (L-Homoarginine-d₄ dihydrochloride) is the d₄-labeled H-HoArg-OH dihydrochloride. H-HoArg-OH dihydrochloride (L-Homoarginine dihydrochloride) is an orally active endogenous non-protein amino acid. H-HoArg-OH dihydrochloride acts as a weak alternative substrate for NOS and interferes with NO production, selectively inhibits tissue-nonspecific alkaline phosphatase (TNAP), and suppresses the uptake of arginine by y⁺-type transporters (system y⁺). H-HoArg-OH dihydrochloride increases tissue hArg concentrations in vivo, regulates amino acid homeostasis, and improves renal function and pathological features of diabetic nephropathy. H-HoArg-OH dihydrochloride can be used in studies related to diabetes and cardiomyopathy.

H-HoArg-OH (Standard) (L-Homoarginine (Standard)) is the analytical standard of H-HoArg-OH (HY-W008385). This product is intended for research and analytical applications. H-HomoArg-OH (L-Homoarginine) is an orally active endogenous non-protein amino acid. H-HomoArg-OH acts as a weak alternative substrate for NOS and interferes with NO production, selectively inhibits tissue-nonspecific alkaline phosphatase (TNAP), and suppresses the uptake of arginine by y⁺-type transporters (system y⁺). H-HomoArg-OH increases tissue hArg concentrations in vivo, regulates amino acid homeostasis, and improves renal function and pathological features of diabetic nephropathy. H-HomoArg-OH can be used in studies related to diabetes and cardiomyopathy.

slCeMM1 is a selective SLC16A3 (MCT4) inhibitor. slCeMM1 inhibits lactate transport, induces intracellular lactate accumulation, reduces viability of SLC16A3-dependent cells, and inhibits growth of SLC16A3-dependent cells. slCeMM1 can be used for the research of rheumatoid arthritis and cancer.

AR-C141990 (Compound 30) is a potent blocker of the monocarboxylate transporter MCT1 with a K_i of 4.8 nM. AR-C141990 (Compound 30) inhibits CYP3A4 and CYP2C9 with IC₅₀ values of 16 μM.

AZ1422 is a selective MCT4 inhibitor that can be used in cancer research.

PEG9MA10-PAB10-GalMA10 is a CD147 LYTAC degrader. PEG9MA10-PAB10-GalMA10 binds to the asialoglycoprotein receptor (ASGPR) via its galactose methacrylate domain, mediating its uptake by hepatoma cells. PEG9MA10-PAB10-GalMA10 induces lysosome-dependent degradation of CD147, resulting in concurrent loss of associated MCT1 and MCT4. PEG9MA10-PAB10-GalMA10 reduces extracellular lactate levels, increases intracellular lactate accumulation, inhibits glycolytic activity, and enhances mitochondrial respiratory capacity. PEG9MA10-PAB10-GalMA10 decreases the secretion of MMP-2 and MMP-9, and upregulates the expression of E-cadherin. PEG9MA10-PAB10-GalMA10 exhibits anti-tumor efficacy in hepatoma models. PEG9MA10-PAB10-GalMA10 can be used for research on liver cancer (hepatocellular carcinoma).

Syrosingopine (Su 3118) is an orally active lactate transporters (MCT1/MCT4) dual inhibitor, which can reduce glycolysis and induce synthetic lethality in cancer cells when combine with metformin. Syrosingopine shows anti-hypertensive activity by depleting peripheral stores of norepinephrine.

MCT4-IN-2 is an orally active monocarboxylate transporter MCT4 inhibitor. MCT4-IN-2 inhibits the activity of MCT4. MCT4-IN-2 can be used for the research of inflammatory diseases, proliferative diseases and pulmonary fibrosis.

H-HomoArg-OH hydrochloride (Standard) is the analytical standard of H-HomoArg-OH hydrochloride (HY-W012340). This product is intended for research and analytical applications. H-HomoArg-OH hydrochloride (L-Homoarginine hydrochloride) is an orally active endogenous non-protein amino acid. H-HomoArg-OH hydrochloride acts as a weak alternative substrate for NOS and interferes with NO production, selectively inhibits tissue-nonspecific alkaline phosphatase (TNAP), and suppresses the uptake of arginine by y⁺-type transporters (system y⁺). H-HomoArg-OH hydrochloride increases tissue hArg concentrations in vivo, regulates amino acid homeostasis, and improves renal function and pathological features of diabetic nephropathy. H-HomoArg-OH hydrochloride can be used in studies related to diabetes and cardiomyopathy.

AR-C117977 is a potent monocarboxylate transporter (MCT1) inhibitor. AR-C117977 prolongs the survival of skin and heart sllograft. AR-C117977 inhibits the development of transplant arteriosclerosis in aortic allografts partially, but was unable to inhibit alloantibody production after transplantation. AR-C117977 shows potent immunosuppressive properties in vivo effectively preventing acute but not chronic allograft rejection in the mouse.

AZD3965 (Standard) is the analytical standard of AZD3965 (HY-12750). This product is intended for research and analytical applications. AZD3965 is a selective MCT1 inhibitor with a K_i of 1.6 nM, showing 6-fold selectivity over MCT2.

α-Cyano-4-hydroxycinnamic acid (Standard) is the analytical standard of α-Cyano-4-hydroxycinnamic acid (HY-107641). This product is intended for research and analytical applications. α-Cyano-4-hydroxycinnamic acid (α-Cyano-4-hydroxycinnamate) is a potent and non-competitive inhibitor of monocarboxylate transporters (MCTs). α-Cyano-4-hydroxycinnamic acid inhibits mitochondrial pyruvate transporter with a K_i of 6.3 μM. α-Cyano-4-hydroxycinnamic acid is used as a matrix to facilitate peptide ionization in matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry applications.